Civica Rx and Xellia Pharmaceuticals to Produce Essential Antibiotics to Reduce Chronic Drug Shortages
Antibiotics mark first release since Ochsner and partners formed Civica Rx
NEW ORLEANS – Today, Civica Rx (Civica, Inc.) and Xellia Pharmaceuticals announced a product supply agreement under which Xellia will manufacture essential antibiotics, including Vancomycin and Daptomycin, for Civica’s member health systems.
Earlier this year, Ochsner Health System (Ochsner) announced that it was one of the founding members of Civica Rx, a new not-for-profit generic drug company established to address chronic shortages of generic drugs and related high prices.
This marks the first time that Civica is announcing the production of generic drugs – and the initial medications to be supplied – since the company launched in late 2018. It has committed to partnering with suppliers to deliver 14 essential generic medications this year. Shortages of these anti-infective medications, like Vancomycin and Daptomycin, are impacting patient care in hospitals across the United States
Ochsner and its patients have been affected by several of these situations, including shortages of some IV antibiotics used to treat severe infections, specific local anesthetics required for common surgical procedures and non-opioid pain management medications. The highly-collaborative initiative will result in lower costs and more predictable supplies of many medicines, helping ensure that patients and their needs come first in the generic drug marketplace.
Headquartered in Copenhagen, Denmark, Xellia will help avoid drug shortages and enable the supply security Civica and its member health systems, like Ochsner, are seeking. The company has a long-standing heritage of manufacturing with an emphasis on quality and security of supply. They also produce their own active pharmaceutical ingredients, as well as finished injectable drug products for serious and often life-threatening bacterial and fungal infections. Xellia will make medications for Civica under Xellia’s Abbreviated New Drug Application (ANDA) and Civica labeling and New Drug Code (NDC).
Civica Rx represents approximately 900 hospitals across the United States whose focus is to address national drug shortages and high prices of life-saving medications. Civica Rx is partnering with FDA approved suppliers in the short-term and working towards becoming a Food and Drug Administration (FDA)-approved manufacturer. ###
Ochsner Health System is Louisiana’s largest non-profit, academic, healthcare system. Driven by a mission to Serve, Heal, Lead, Educate and Innovate, coordinated clinical and hospital patient care is provided across the region by Ochsner's 40 owned, managed and affiliated hospitals and specialty hospitals, and more than 100 health centers and urgent care centers. Ochsner is the only Louisiana hospital recognized by U.S. News & World Report as a “Best Hospital” across three specialty categories caring for patients from all 50 states and more than 70 countries worldwide each year. Ochsner employs nearly 25,000 employees and over 4,500 employed and affiliated physicians in over 90 medical specialties and subspecialties and conducts more than 700 clinical research studies. Ochsner Health System is proud to be a tobacco-free environment. For more information, please visit ochsner.org and follow us on Twitter and Facebook.